Telix Pharmaceuticals Reports Strong Q1 Revenue and Significant Pipeline Advancements
TLX sits 51% above its 52-week low of $6.28 on light trading volume (0.3× avg).
Summary
Telix Pharmaceuticals announced strong Q1 2026 unaudited group revenue of US$230 million, reaffirmed its FY 2026 guidance, and provided positive updates on multiple clinical trials and regulatory submissions for its therapeutics pipeline.
Key Events · Earnings and Guidance · TLX
-
Strong Q1 2026 Revenue Growth
Unaudited Group revenue reached US$230 million, an 11% increase quarter-over-quarter, with Precision Medicine revenue growing 16% quarter-over-quarter to US$186 million.
-
FY 2026 Guidance Reaffirmed
The company reiterated its full-year revenue guidance of US$950 million to US$970 million, along with R&D expenditure guidance of US$200 million to US$240 million.
-
Therapeutics Pipeline Progress
Part 1 of the ProstACT® Global Phase 3 study for TLX591-Tx met safety and dosimetry objectives. Additionally, a New Drug Application (NDA) for TLX101-Px was resubmitted to the FDA, and a Marketing Authorization Application (MAA) was filed in Europe.
-
Advanced Clinical Trials and Regulatory Milestones
Significant progress was reported across other therapeutic candidates, including the opening of clinical sites for TLX250-Tx and TLX101-Tx pivotal trials, expansion of TLX090-Tx study sites, and an NDA acceptance for TLX591-Px in China. The company is also targeting a H1 BLA resubmission for TLX250-Px.
Analysis · TLX · Life Sciences
This 6-K filing provides a comprehensive update on Telix Pharmaceuticals' strong Q1 2026 performance, including robust revenue growth and significant progress across its therapeutics pipeline. While the top-line revenue figure was previously reported in news, this official filing details the breakdown of revenue, reaffirms full-year guidance, and provides critical updates on multiple clinical trials and regulatory submissions. For a life sciences company, demonstrating both commercial execution and pipeline advancement is crucial, making these updates highly material for investors.
How filings like this one have moved
In the 30 days to Sep 12, 2026, 35.9% of the 1612 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.19%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TLX was trading at $9.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3B. The 52-week trading range was $6.28 to $20.00. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.